Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial

Journal of Bone and Mineral Research

Volumn 24, Issue 1, 2009, Pages 153-161

  Brown, Jacques P ^a   Prince, Richard L ^b   Deal, Chad ^c   Recker, Robert R ^d   Kiel, Douglas P ^e   De Gregorio, Luiz H ^f   Hadji, Peyman ^g   Hofbauer, Lorenz C ^h   Álvaro Gracia, Jose M ⁱ   Wang, Huei ^j   Austin, Matthew ^j   Wagman, Rachel B ^j,k   Newmark, Richard ^j   Libanati, Cesar ^j   San Martin, Javier ^j   Bone, Henry G ^l  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f SYNARC/CCBR   (Brazil)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j AMGEN INC   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Michigan Bone and Mineral Clinic   (United States)

more..

Author keywords

Alendronate; Biochemical markers of bone turnover; BMD; Denosumab; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; DENOSUMAB; PLACEBO; VITAMIN D;

ABSCESS; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST INFECTION; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EAR INFECTION; FEMALE; FEMUR NECK; GREATER TROCHANTER; HIP; HUMAN; KIDNEY CARCINOMA; LABORATORY TEST; LIVER METASTASIS; LOCALIZED INFECTION; LUMBAR SPINE; LUNG SMALL CELL CANCER; METASTASIS; MULTICENTER STUDY; MYCOSIS FUNGOIDES; OVARY CANCER; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PSEUDOMEMBRANOUS COLITIS; PYELONEPHRITIS; RADIUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UROSEPSIS; VAGINA CANCER; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; RANK LIGAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149099647     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.0809010     Document Type: Article

References (32)

1. NIH Consensus Development Panel on Osteoporosis Prevention 2001 Diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
2. Huot L, Couris CM, Tainturier V, Jaglal S, Colin C, Schott AM 2008 Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 19:1047-1054.
3. Stafford RS, Dricling RL, Hersh AL 2004 National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 164:1525-1550.
4. Watson J, Wise L, Green J 2007 Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63:843-849.
5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
6. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
7. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832-1839.
8. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
9. Harris ST, Blumentals WA, Miller PD 2008 Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245.
10. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M. Chesnut CH 111, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344- 1352.
11. Kanis JA, Barton IP, Johnell O 2005 Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16:475-482.
12. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A 2008 Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681-686.
13. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549.
14. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
15. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delancy J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
16. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
17. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157.
18. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22:1832-1841.
19. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831.
20. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 43:222-229.
21. Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, Jawa V, Koren E, Swanson SJ 2005 Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 51:1983-1985.
22. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC II 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
23. Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC 2003 Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin 19:383-394.
24. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Oin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461-468.
25. Hochberg Y 1988 A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
26. The International Society for Clinical Densitometry Introduction to the understanding of bone densitometry. Available online at http://www.iscd.org/ visitors/resources/IntroBoneDens.ppt. Accessed May 20, 2008.
27. Russell RG, Walts NB, Ebetino FH, Rogers MJ 2008 Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759.
28. Miller PD, Epstein S, Sedarati F, Reginster JY 2008 Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin 24:207-213.
29. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
30. Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE 2004 Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20:2031-2041.
31. Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ 2007 RANKL inhibition: From mice to men (and women). Adv Exp Med Biol 602:143-150.
32. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066.